Abstract: Objective To observe the clinical efficacy and safety of entecavir combined with liraglutide in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes. Methods One hundred patients with hepatitis B cirrhosis and liver-derived diabetes were divided into a test group（routine treatment + Entecavir + liraglutide treatment） and a control group（routine treatment and liraglutide） with a random number table method, each with 50 cases. We were admitted to our hospital from May 2018 to May 2019. By analyzing the liver function, blood glucose level, and incidence of adverse reactions of patients before and after treatment, the clinical efficacy and safety of different drugs in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes were evaluated. Results After treatment, the levels of direct bilirubin（DBIL）, alanine aminotransferase（ALT）, aspartate aminotransferase（AST）, and total bilirubin（TBiL） of the subjects showed a downward trend, and the test group was significantly lower than the control group（P<0.05）; After treatment, the levels of glycosylated hemoglobin（HbA_1c）, fasting blood glucose（FBG）, and 2 h postprandial blood glucose（2 hPBG） of the subjects showed a downward trend. The test group was significantly lower than the control group（P<0.05）. There was no significant difference in incidence ofadverse reactions between the two groups（P>0.05）. Conclusion The administration of entecavir and liraglutide can reduce the adverse reactions and blood glucose, and improve the antiviral effects, liver function and treatment safety. This method is worthy of clinical application and promotion.

Key words: Hepatitis B cirrhosis, Entecavir, Liraglutide, Liver-derived diabetes